Women face different gynecological disorders at some point or the other in their life. However, most of the disorders can be healed but in many cases, they proved to be fatal because of the late diagnosis. Currently, the global women health therapeutics market possesses a notable pipeline of the various molecules at different stages of clinical development. Some of these molecules include teriparatide, vaginorm, ASP1707, elagolix, abaloparatide, romosozumab, and others.
The rising incidences of lifestyle-associated diseases in women is one of the major factors driving the growth of the global women’s health therapeutics market. Moreover, there is significant growth in the investment in the healthcare sector for the early detection of infectious and cancer diseases to facilitate proper treatment at the right time. However, the growing complications associated with pregnancy along with the launch of effective drugs are further likely to promote the growth of the market globally. The growing awareness among people regarding women’s health will also help the market to prosper vigorously in the forthcoming years.
The global women’s health therapeutics market can be segmented into application, drug, type, and region.
By application, the market can be segmented into polycystic ovary syndrome, menopause, contraceptives, endometriosis, postmenopausal osteoporosis, hormonal infertility, and others.
By drug, the market can be segmented into ORTHO TRI-CY LO (28), ACTONEL, premarin, FORTEO, nuvaring, minastrin 24 Fe, aclasta, zometa, mirena, prolia, XGEVA, and EVISTA.
By type, the market can be segmented into oncology, pregnancy, and infection. The oncology segment accounts for the largest share in the global women’s health therapeutics market. The oncology segment can be further bifurcated into vaginal & vulvar, uterine, ovarian, and cervical cancer.
North America accounts for the largest share in the global women’s health therapeutics market due to the growing incidences of gynecological disorders in the region. Moreover, the growing funding and initiatives from the government to improve women’s health will further propel the growth of the regional market.
Asia Pacific is expected to witness a significant growth rate in the forthcoming years due to the growing aging population in the region. Moreover, the growing disposable income of the people is also likely to promulgate the growth of the regional market.
Some of the significant players in the global women health therapeutics market are CooperSurgical, Inc., Sun Pharmaceutical Industries Ltd., Sanofi, Mylan N.V., GlaxoSmithKline plc, Eli Lilly and Company, Novartis AG, AstraZeneca, Bristol-Myers Squibb Company, Merck and Co., Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical, Pfizer, Inc., and Bayer AG. To cite, Teva Pharmaceutical in August 2016 acquired Actavis Generics to strengthen their generic medicines portfolio. The company is the leader in specialty drugs categories like ParaGard pertaining to therapeutics.
